The purpose of this review article is to describe the underlying methodology for successfully translating novel interfaces for electrical modulation of the peripheral nervous system (PNS) from basic design concepts to clinical applications and chronic human use. Despite advances in technologies to communicate directly with the nervous system, the pathway to clinical translation for most neural interfaces is not clear. FDA guidelines provide information on necessary evidence which should be generated and submitted to allow the agency evaluate safety and efficacy of a new medical device. However, a knowledge gap exists on translating neural interfaces from preclinical studies into the clinical domain. Our article is intended to inform the field on some of the key considerations for such a transition process specific to neural interfaces that may not be already covered by FDA guidances. This framework focuses on non-penetrating peripheral nerve stimulating electrodes that have been proven effective for motor and sensory neural prostheses and successfully transitioned from pre-clinical through first-in-human and chronic clinical deployment. We discuss the challenges of moving these neural interfaces along the translational continuum and ultimately through FDA approval for human feasibility studies. Specifically, we describe a translational process involving: quantitative human anatomy, neural modeling and simulation, acute intraoperative testing and verification, clinical demonstration with temporary percutaneous access, and finally chronic clinical deployment and functional performance. To clarify and demonstrate the importance of each step of this translational framework, we present case studies from electrodes developed at Case Western Reserve University (CWRU), specifically the spiral cuff, the Flat Interface Nerve Electrode (FINE), and the Composite FINE (C-FINE). In addition, we demonstrate that success along this translational pathway can be further expedited by: appropriate selection of well-characterized materials, validation of fabrication and sterilization protocols, well-implemented quality control measures, and quantification of impact on neural structure, health, and function. The issues and approaches identified in this review for the peripheral nervous system may also serve to accelerate the dissemination of any new neural interface into clinical practice, and consequently advance the performance, utility, and clinical value of new neural prostheses or neuromodulation systems.
Introduction
Robust and effective two-way communication with the nervous system is important both clinically and scientifically. With the growing number of people with motor impairments, limb loss, and paralysis there is a significant clinical need for reliable and robust motor and sensory neural prostheses that could be employed outside of the laboratory setting. The number of people who live with severe motor disability, such as spinal cord injury, or who have sustained a limb loss is estimated to exceed 2.2 million in the United States alone (Singh et al., 2014; Ziegler-Graham et al., 2008) . In addition, common health complications such as stroke or autoimmune diseases could cause moderate to severe sensorimotor impairments (Brackenridge et al., 2016; Daly et al., 1993; Selkirk et al., 2017) . Although medications and physical therapy may help minimize comorbidities and alleviate symptoms, restoring lost or compromised function often requires new interventions that physically reconnect existing neural circuitry in the body to implanted or external devices via neural interfaces (Benabid et al., 1994; Bittar et al., 2005; Briggs et al., 2008; Creasey et al., 2001; Fisher et al., 2008; Kenney et al., 2002; Peckham et al., 2001; Thomson et al., 2013) .
In addition to their potential clinical significance, neural interfaces also play an important role in advancing our scientific understanding of the nervous system in ways not previously possible. For example, recording and stimulation techniques from the PNS have provided us with new insights on motor control (Clark et al., 2011; Micera et al., 2011; Weber et al., 2011) , decoding the neural basis of touch (Graczyk et al., 2016) , understanding the peripheral pathways for pain (Keller and Krames, 2009) , and elucidating the role of autonomic nervous system in regulating biomarkers associated with autoimmune diseases (Koopman et al., 2017) . The resulting knowledge could expand the application of available neural interfaces to new target populations or aid in developing more successful treatments for neurological diseases that were previously uncharacterized or not well understood (Charkhkar et al., 2018; Pavlov and Tracey, 2017; Weber et al., 2012; Zanos et al., 2018) .
Approaches to directly interface with the PNS reported to date (Boretius et al., 2010; Branner et al., 2001; Branner and Normann, 2000; Malagodi et al., 1989; Naples et al., 1988; Stein et al., 1975; Tyler and Durand, 2003) can be divided into three broad categories: penetrating, non-penetrating, and regenerative electrodes (Rijnbeek et al., 2018; Spearman et al., 2018) . Non-penetrating peripheral nerve interfaces (i.e., cuff electrodes) wrap around the nerve and intimately couple the electrode to the epineurium, whereas penetrating electrodes disrupt the epineurium, and in some cases the perineurium, to allow closer proximity to the fascicles or the axons within them. Regenerative interfaces are placed between two ends of a severed nerve that must grow through the electrode to re-establish functional connections. Despite numerous pre-clinical PNS studies demonstrating the feasibility of such interfaces, few have successfully transitioned to chronic clinical applications. Hence, there is a need for guidelines that illustrate the required steps for transitioning any neural interface, existing or emerging, from concept to clinical deployment.
In this review, we focus on non-penetrating nerve cuff electrodes as examples of technologies which have successfully navigated the translational process and shown consistent chronic clinical performance in various applications, such as suppressing pain (Picaza et al., 1977) , assisting respiration (Glenn and Phelps, 1985) , treating intractable epilepsy (Terry et al., 1990) , and facilitating micturition (Brindley et al., 1986 (Brindley et al., , 1982 . Nerve cuffs have also been applied to motor system neural prostheses to restore hand and arm function after tetraplegia, and standing or stepping function after paralysis from paraplegia (Fisher et al., 2008; Memberg et al., 2014) . Moreover, nerve cuff interface technologies have recently been successfully applied to restore discrete tactile sensations to individuals with upper or lower limb loss (Charkhkar et al., 2018; Tan et al., 2014) .
Successful translation of a neural interface for neuroprosthetic or neurotherapeutic applications from concept to clinical deployment highly depends on thoroughly developed early design criteria. Therefore, series of important and key considerations should be recognized and reviewed prior to any prototyping or animal testing. Some of these factors include but are not limited to: minimal impact on neural health, intimacy with the underlying neural structures, ability to selectively activate independent nerve fibers, consistent stimulated responses, and mechanical stability especially in target implant locations exposed to large or repetitive stresses. These issues are especially important chronically over time scales spanning months and years. Yet even with well-developed design criteria, the pathway from the benchtop to first-in-man deployment can be challenging and often unclear. Therefore, we propose a conceptual framework for the development of neural interfaces for motor or sensory neuroprostheses (Fig. 1 ) that details the intermediate steps of a translational process starting with pre-clinical studies and resulting in clinical implementation. A summary of key considerations in every step is provided in Table 1 .
Pre-clinical studies are the first step in testing the underlying concept of a new design and ascertaining the biocompatibility of the constituent materials and examining the functionality of the device both in vitro and in vivo. Consequently, human cadaver studies should be performed to document the morphology and fascicular structure of targeted peripheral nerves. Such quantitative neuroanatomical studies establish the design space for a peripheral nerve electrode intended for a specific human neural target.
Computer simulations require realistic computational models of the nerve so that electrode-nerve interactions can be represented mathematically and manipulated to optimize electrode configuration in terms of the size, geometry, electrochemical behavior, and the number and location of contacts. The findings from quantitative neuroanatomical studies enable the development of anatomically-based neural models to gain insight into the functional implications of a proposed electrode design.
The next step in this translational framework involves verifying the acute operation of the neural interface. The selectivity and generalizability of an electrode configuration predicted by anatomically-based modeling and simulation studies must be compared against experimental data obtained during acute intraoperative tests. Design changes are often identified at this stage, which may or may not require repetition of the earlier analyses to refine characteristics of the device. Throughout these initial phases of the translational pathway, device design histories need to be maintained under an FDA-inspired quality system consisting of formal design controls ("Design control guidance for medical device manufacturers", 1997). Material qualifications and suppliers need to be specified and repeatable prototype manufacturing procedures need to be developed and documented so that prototype devices suitable for pre-clinical and acute use can be certified as "human grade" experimental devices. Similarly, packaging and sterilization protocols need to be established, and validated cleaning and pyrogenicity tests must be performed to regulatory standards prior to chronic deployment. Long-term monitoring of the interface and the ultimate functional benefits of neural interface designs to the end user requires chronic implantation. This can be approached in two separate stages. The first stage involves a temporary percutaneous phase that allows easy access to electrode contacts via externalized leads. This phase permits extensive testing using an external stimulator to perform exploratory studies and fine tuning, prior to chronically installing an implanted pulse generator (IPG). Longitudinal studies involving long-term followup determine the chronic safety, robustness, and clinical performance of the implanted system. At the end of the process, the preliminary safety profile and indication of clinical utility of the neural interfaces are known with sufficient certainty to design and conduct the pivotal clinical trials that will establish the safety and efficacy of a new implanted intervention for pre-market approval by FDA.
The framework presented in this review is a summary of the process successfully employed at CWRU for stimulating peripheral nerve cuff electrodes. Our goal is to provide a guideline with detailed examples at every step to depict a translational pathway toward clinical introduction of any new or existing neural interface.
Conceptual designs and pre-clinical studies
The design process for any new neural interface starts with outlining the desired features. Pre-clinical studies using in vitro and in vivo prototypes provide valuable information on how the initial conceptual designs should be modified. Acute proof-of-concept studies need to be complemented by chronic testing in freely moving animals over the course of weeks and months. Self-sizing spiral nerve cuffs, shown in Fig. 2A , were among the significant iterations in non-penetrating peripheral nerve technology because of their non-compressing feature. They can be rolled around the nerve and their adjustable size can accommodate changes in nerve diameter due to acute swelling after the implant surgery (Grill and Mortimer, 1996; Naples et al., 1988; Veraart et al., 1993) . Chronic animal studies suggested that multi-contact spiral cuffs were able to selectively activate fascicles of a nerve trunk of feline animal models (Grill and Mortimer, 1998) . Selectivity is the ability to recruit a specific subset of neural fibers and it is a desired feature for a neural interface, especially for applications in where successful motor control could only be achieved through recruitment of specific downstream muscles, and sensory fibers need to be isolated for activation. Post-mortem examination of the nerves instrumented with nerve cuffs suggested some signs of trauma involving the proliferation of subperineural connective tissue and reduced axonal density (Agnew et al., 1990; Naples et al., 1990) , but the implanted animals exhibited normal movement patterns with no evidence of altered motor function.
Although the circular cross section of the spiral cuff appropriately fits cylindrically-shaped peripheral nerve branches, it is a less suitable interface for broad, flat nerves that contain many fascicles (i.e., the proximal human femoral nerve trunk or human sciatic nerve). A cylindrical or spiral cuff could reshape such nerves into a circular cross section which would relocate some of the fascicles closer to the center and farther away from the cuff contacts on the perimeter (Choi et al., 2001) . Various schemes were proposed to recruit deep fascicles prior to superficial fascicles, and some have successfully isolated individual fascicles (Grill and Mortimer, 1996; Veraart et al., 1993) . These approaches mainly rely on delivery of carefully-timed stimulation pulses on different contacts of the cuff to steer the electrical field within the nerve to target the deep fascicles (Grill et al., 1991; Grill and Mortimer, 1995) . However, few implanted pulse generators suitable for chronic human use are capable of generating such waveforms for motor neuroprosthetic applications.
The need for selectively activating interior neural structures deep to the epineurium with simple monopolar stimulus waveforms, and the tendency of large human nerve trunks to assume more oval cross-sectional shapes, inspired the development of flat cuff electrodes. Early analytical studies comparing stimulation and recording selectivity Table 1 Summary of key considerations for every step of the translational framework presented in Fig. 1 (Perez-Orive and Durund, 2000) . FINE cuffs had a rectangular cross-sectional profile ( Fig. 2B ) and were designed to reshape circular nerves and retain the natural shapes of broad flat nerves (Tyler and Durand, 2002; Yoo and Durand, 2001 ). Gentle persistent pressure from the FINE causes the fascicles to rearrange into a linear configuration resembling a ribbon cable because of the relatively loose connective tissue between them. Maintaining the same cross-sectional area while reshaping from circular to oval configuration necessitates an increase in the perimeter, allowing contacts to be located more densely on the interior of the cuff. Thus, reshaping locates fascicles closer to the electrode contacts and allows higher contact density to further improve selectivity. Preserving the original nerve cross-sectional area and limiting the height of the lumen of the FINE to be larger than the diameter of the largest fascicle (conservatively 1.0 mm) does not apply internal pressures sufficient to compromise blood flow and hence does not cause significant physiological or histological damage to the nerve (Tyler and Durand, 2003) .
With the nerve in a flat, ribbon-like configuration, simple monopolar, square-wave pulses can independently activate each fascicle more selectively than with the same nerve in a circular cross-section with field steering (Leventhal and Durand, 2003) , hence relaxing the design restraints on the stimulator and reducing the time-consuming process of tuning steering currents to isolate specific fascicles.
To function well and be minimally disruptive to healthy neural function, peripheral nerve cuff electrodes need to be flexible along their lengths in order to accommodate bending and sliding with joint motion, particularly near tight anatomical places such as the inguinal ligament over the proximal femoral nerve, or the wrist and elbow. Longitudinal flexibility was a shortcoming in many nerve cuff designs from early cylindrical configurations to the CWRU Spiral and FINE. A new electrode was conceived that incorporated the reshaping and morphology matching properties of the FINE while offering enhanced longitudinal flexibility. The Composite-FINE (C-FINE) achieved this design goal by employing a layered construction similar to the CWRU Spiral, while promoting or maintaining a central oval cross section (Figs. 2C & 2D). A silastic bilayer "sandwich" design was devised which incorporated embedded biocompatible polymer bars located centrally over the electrode contacts (Fig. 3) . This resulted in a stiffer reshaping or shape matching central region to maintain intimate contact with the epineurium while simultaneously provided ultra-flexible regions proximally and distally to accommodate bending along the length of the nerve. By changing the size, thickness, and location of the polymer stiffening bars, the spatial compliance of the electrode can be easily reconfigured for any neural target. The polymer bars are also compatible with metal deposition microfabrication techniques for high A series of pre-clinical in vitro and in vivo investigations were conducted to thoroughly document performance and biological responses to the C-FINE. The long-term biological response to the C-FINE on the peripheral nerve was established through chronic (1 month) testing with freely moving animals . These devices were implanted on the sciatic (6) and median (4) or ulnar (2) nerves near the hip and shoulder joints of three adult cats. No marked histological changes to any nerve within, near the edges or proximal/distal to the cuffs were observed after three months of implantation. The histological analysis of the nerves after explant revealed minimal tissue reaction and encapsulation, and myelination appeared to be normal (Fig. 4) . Clusters of large, thickly myelinated axons were present, as opposed to smaller, more thinly myelinated fibers that would characterize either ongoing neural damage or repair and regeneration processes (Baba et al., 1982; Schröder, 1972) . Nerve conduction velocities in all 12 nerves were within normal limits (66.6 ± 7.3 m/s) at explant and unchanged by the presence of the C-FINE when compared to initial values. Furthermore, no signs of distress or altered behaviors were observed in the animals, which resumed and maintained expected levels of normal activity immediately post-implantation. These results confirm that the presence of the C-FINE is well tolerated and causes no discernible changes to normal nerve function .
Long-term selectivity of the C-FINE was also demonstrated through chronic animal testing lasting months or years. Neural stimulation delivered via 16-contact C-FINE implanted on sciatic nerves in a feline model resulted in consistent and selective recruitment of at least five major downstream muscles with stable joint moments until explantation at 24 months (Gelenitis et al., 2019) . In another set of chronic biocompatibility tests, the stability of the stimulated responses of the C- . FINE was determined in three non-human primates (Brill et al., 2018) where seven individual upper extremity muscles could be selectively and consistently activated for the study period of three months. At no time did the animals exhibit any observable signs of discomfort or compromised voluntary motor activity due to the presence of the CFINEs.
The results from these pre-clinical studies were essential to refine initial neural interface design, to assess the performance and biological responses to the device, and to gather sufficient supporting data required for FDA Investigational Device Exemption (IDE) submission prior to planning any chronic clinical studies in human subjects. In developing in vitro and in vivo tests to determine biocompatibility of a new neural interface, the FDA guideline 'Use of International Standard ISO-10993′ should be considered (FDA Center for Devices and Radiological Health, 2016) . This guideline outlines the considerations for biocompatibility testing of a medical device.
Quantitative human anatomy
Identification of the branching pattern, pre-and post-branch diameters, and fascicular anatomy of the nerves targeted for instrumentation with neural interfaces provides accurate estimates to design safe and appropriately sized electrodes. Additionally, the same anatomical measurements specify parameters for computational modeling and simulation of the expected performance of the interface in silico, enable the assessment of surgical access, maximize long-term electrode stability, and reduce the time spent under anesthesia.
Nerve health and charge delivery could be negatively affected postimplant if the installed cuff electrode does not match the size of the target nerve. An electrode larger than the nerve diameter may not make intimate contact with the epineurium, resulting in poor electrode-nerve coupling, thus requiring more current to activate the underlying axons than electrodes closer to the nerve (Mahnam et al., 2009 ). Conversely, a cuff electrode smaller than the diameter of the neural target can exert added pressure on the nerve and damage the neural tissue. Findings from prior anatomical studies have shown that 30 mmHg of compression for 270 min can result in a 70% reduction in action potential amplitude, and 60 mmHg for 150 min can cause a complete loss of neural activity (Hargens et al., 1993; Szabo and Sharkey, 1993) . Intraneural pressure as high as 70 mmHg can cause complete loss of compound muscle action potentials after only 55 min of compression (Nitz et al., 1986) . These sizing boundaries led to the adoption of the industry standard and FDA acceptable cuff-to-nerve diameter ratio (CNR) of 1.5 (Ducker et al., 1968) . Such standards for rigid cylindrical cuffs must be re-envisioned for self-sizing or compliant neural interfaces. Given prior literature on acceptable and damaging intraneural pressures, we designed a series of tests to characterize the pressure exerted on a swelling nerve by a compliant neural interface. Mylar reservoirs placed inside of C-FINES of various sizes were inflated with saline while monitoring internal pressure and electrode deformation . At the industry CNR standard of 1.5, the results showed that human-grade C-FINEs exerted only 10 mm Hg of pressure on the nerve, far below the value which would compromise intrafascicular blood flow and cause acute neural damage (Dahlin, 1991; Rydevik et al., 1981) . These data suggested that the C-FINE could safely accommodate acute or chronic post-operative swelling due to surgical manipulation or other trauma without adversely affecting neural perfusion.
Previous studies of morphology and fascicular structure of the human femoral (Gustafson et al., 2009) , sciatic (Gustafson et al., 2012) , ulnar, median, and radial nerves (Brill and Tyler, 2017) in embalmed human cadaver specimens helped to identify parameters for modeling studies and optimize cuff design for clinical deployment in these anatomical locations. In these studies, length, major and minor diameters, and branching patterns of the nerves were measured in situ. Consequently, the nerve samples were histologically processed and stained for individual fascicles. Detailed information such as the number of fascicles, fascicular area, and diameter were calculated by processing the nerve cross-section images. The fascicle and axon sizes and their distributions were collated for use in subsequent computational modeling. Fascicle tracing from muscle to plexus was possible by imaging longitudinal cross-sections. These studies showed that fascicular representations remain consistent between distal and proximal nerves (Gustafson et al., 2009 ). Interestingly, it was revealed as mammals increase in size, fascicle number, rather than fascicle diameter, increases (Gustafson and Artis, 2005) . This observation highlights the importance of human anatomical studies rather than generalizing measurements obtained from small-animal models. It was also determined that in the femoral nerve, one of the largest diameter nerves in the body, 91% of fascicles had effective diameters below 700 μm and no fascicles had a diameter greater than 1 mm. This information was considered during the design of the C-FINE and FINE, such that the smallest cuff size accommodated nerves with fascicles as large as 1 mm without compromising the intrafascicular blood flow.
Human anatomical studies were also crucial for surgical planning and ensuring long-term electrode stability. When the upper-limb extremities are the neural target, implanted electrodes are subjected to small volumes, tight subcutaneous fascial planes, and little adipose, as well as regular bending and translational movements of the nerve imposed by the elbow and shoulder joints. Major concerns for surgical installation and chronic device performance of cuffs installed on the femoral nerve in lower limb include proximity to the inguinal ligament in the proximal anterior thigh and ill-described branching patterns of the upper femoral nerve serving both hip flexors and knee extensors (Freeberg, 2018) . Proximity of the neural targets to major blood vessels is also a concern and careful planning is required to minimize the risk of secondary complications.
Finally, knowledge of human anatomy could increase the efficiency in the operating room and reduce the time spent under anesthesia. Identifying the optimal implant location before surgery can lead to fewer and/or smaller surgical incisions and thus accelerate the recovery process. Findings from the target nerve branching patterns and branchfree lengths help in determining suitable surgical access points. As stated above, cuff electrodes are designed according to the dimensions of the target nerve. This ensures that the electrode will have intimate contact with the epineurium while minimizing the potential of nerve compression. On a practical level, it minimizes the number of devices that need to be fabricated and sterilized because the range of sizes to accommodate the target locations for a given population can be anticipated. Once the target nerve is exposed and measured intraoperatively, the device with the most similar dimensions can be installed. Streamlining this process decreases the time spent under anesthesia, which minimizes the risk of infection and other potential surgical complications.
In summary, the findings from quantitative anatomical studies provide valuable information to scale the dimensions, reconfigure the geometry of recording and/or stimulating contacts, identify the most suitable anatomical locations, and plan efficient surgical approaches for installing the device in humans. Quantifying the inherent variability of the underlying neuroanatomy at this stage also facilitates generalizing the neural interface for the population at large. These anatomical data are the necessary prerequisites for the next stage of the translation process.
Modeling and simulation
Computational models are useful tools to evaluate and optimize contact placement within a neural interface as well as to examine the expected selectivity in fiber recruitment prior to implanting the device in human subjects. Textbook representations of peripheral nerve anatomy, as well as CNS structures, are often incomplete generalizations that need to be augmented through computer modeling and simulation studies to gain confidence in and make predictions about the ultimate performance of new interfaces in humans. Here, we discuss examples of in silico evaluation of FINEs installed on distinct neural targets in lower limb, including femoral and sciatic nerves. These examples illustrate how a simulated neural interface can provide valuable information regarding the potential impact of various design considerations, and predict performance outcomes that can be expected when the device is clinically deployed.
The sensitivity of a neural interface's performance to the number, density, and location of stimulating electrode contacts, the relative size of the cuff, and the ability to selectively activate the targeted fascicles without a priori knowledge of the specific internal organization of a given nerve can be assessed by combining finite element modeling (FEM) of nerve cuff geometry with neural modeling of axonal activation dynamics. To address the design considerations for the proximal femoral nerve, a FEM of the FINE (Fig. 5 ) was constructed with a rectangular geometry, silicone as the bulk material, and square platinum contacts with areas of 0.25 cm 2 separated by 1 mm, which were considered to be within the capabilities of fabrication techniques at the time of the study (Schiefer et al., 2008) . Spatially distributed electrical potentials were computed at every FEM mesh node, and then applied to a double cable model of a mammalian axon (McIntyre et al., 2002) in saline to determine the fiber activation profile in response to stimulus delivered at any selected contact. Constituent electrical conductivities of the epineurium, perineurium, endoneurium, and other tissues were adapted from the previously reported values for the same compartments (Choi et al., 2001 ). The geometric distribution of fascicles within the volume of the cuff were assumed to be that of the common femoral nerve trunk, as determined in the previously described quantitative neuroanatomical studies that traced their fascicular pathways from the muscles or end organs to the inguinal ligament. Digital cross sections from multiple human cadaver specimens were digitized for inclusion in the analysis to represent individual variability of the fascicular organization of the nerves. Axons with various diameters and myelin thicknesses from known distributions in human sensory fibers (Behse, 1990 ) and motor fibers (Garven et al., 1962) were distributed within each fascicular region in each model. The effect of relative cuff size with respect to the nerve was studied by repeating the simulations with three different FINE heights, each representing loose, snug, and tight fits (3.8 mm, 2.3 mm, and 1.4 mm, respectively) for each cross section. The number of contacts on the FINE and contact locations were also varied. High-density electrodes were simulated with a 22-contact cuff (11 contacts on both the top and bottom). The muscular selectivity of each FINE configuration was computed as the percentage of axons activated within a group of fascicles innervating the same target muscle, similar to the method described in (Choi et al., 2001 ). Finally, the functional implications of different electrode densities were assessed by using a previously validated commercial package for musculoskeletal modeling to predict the forces and joint moments that would be produced by activating the same percentage of each muscle as predicted by the neural simulations (Delp et al., 1990; Friederich and Brand, 1990) .
As expected, the FINE with a smaller internal opening height required smaller magnitude electrical currents to activate the nerve fibers. The simulation results suggested that the highest selectivity for the human femoral nerve was achieved with a configuration of 22 contacts, which was always able to isolate and selectively activate each of the six muscles innervated by the femoral nerve (rectus femoris, vastus lateralis, medialis and intermedius, as well as sartorius and pectineus), regardless of the variations in fascicular organization between the anatomical cross sections. This electrode configuration also generated estimated knee extension moments that would be sufficient for the sitto-stand transition and 70% of the hip flexion moment needed for walking (Schiefer et al., 2008) . Although such results were promising, microfabrication techniques place a constraint on the maximum number of stimulating contacts. Additionally, if these high-density cuffs are implanted bilaterally and/or on multiple nerves, current IPGs do not have enough output channels to deliver stimulation to all contacts. Therefore, the same simulations were repeated with a fewer number of contacts to find an acceptable trade-off between minimizing system Fig. 5 . A finite-element model of a 22-contact FINE on the human femoral nerve integrated with neural modeling of axonal activation dynamics. The fascicular anatomy of the nerve was based on prior quantitative neuroanatomical studies. The 2D cross-sectional view is shown on top and a 3D view is depicted on the bottom. Reproduced with permission of IEEE (Schiefer et al., 2008) . complexity and maximizing muscle selectivity for femoral nerve cuff electrodes. An 8-contact FINE with four evenly spaced contacts facing each other on the opposite sides of the cuff still yielded acceptable performance. The simulated 8-contact FINE was capable of generating more than twice the knee extension moment required for the sit-tostand transition and produced a significant amount of the hip flexion moment needed during gait. These results were robust over multiple nerve models, and the configuration represented a practical alternative that appeared to be generalizable even in the presence of individual variability. The results from any configurations with less than 8 contacts showed significant reduction in predicted selectivity and joint moment generating capacity for this neural target (Schiefer et al., 2008) .
Because there are differences in the quantitative anatomy between nerves, similar analyses were performed with anatomical models of the post-branch tibial and fibular nerves, and pre-branch sciatic nerves (Schiefer et al., 2013 (Schiefer et al., , 2012 . Results from these new neural targets suggest that cuffs installed on pre-branch sciatic nerve may require as many as 30 contacts to selectively activate the distinct muscle groups (without spillover to antagonists) to achieve plantar-and dorsi-flexion of the foot with balanced inversion-eversion. If the implant location is moved more distally to post-branch tibial and common peroneal nerves, simulation results predicted that only eight contacts per cuff could achieve a similar level of selectivity. The same study demonstrated that performance was significantly enhanced and the required contact number was halved with tri-polar stimulation or field steering.
As shown in the examples above, an anatomically realistic numerical model of the nerve combined with finite element analysis of the electrode can accelerate the translation of new neural interfaces into humans by narrowing the design space and predicting the performance after implant. In the absence of a priori information about the organization of an individual nerve or a lack of sufficient anatomical data, probabilistic approaches such as the Monte Carlo method proved to be useful in generalizing the results of computational models (Schiefer et al., 2012) . In these methods, the simulation is repeated over a large set of possible fascicular distributions and the results are aggregated to provide a range of estimated outcomes that could be an indicator of expected variations in the general population.
Overall, these simulation results demonstrate the necessity of customizing the interface design for each new neural target and the level of selectivity desired for a given motor or sensory application. Information from quantitative anatomy of target nerves and realistic computer simulations of electrode-nerve interactions allow for informed decisions to be made about critical factors that help eliminate trial and error from ensuing clinical tests, thus mitigating potential risks and improving the chances of success in the next steps of the translational process.
Acute intraoperative verification
Acute intraoperative testing in human subjects is one of the best methods for predicting the functional performance of a neural interface, particularly for applications in motor neuroprostheses. These studies involve the temporary deployment of a neural interface during routine clinically-indicated surgical procedures that expose the nerve of interest. Performance of the interface should be evaluated in terms of ease or difficulty of surgical approach, selectivity with respect to evoked electromyographic (EMG) activity of the muscles innervated by the nerve of interest, and any other biomarkers or easily measurable outcomes indicating the suitability of the device for chronic implantation. One commonly used method is to recruit individuals who are already scheduled to undergo a surgery that exposes the target nerve of interest. As an example, a nerve interface for the proximal femoral nerve could be intraoperatively tested during a routine femoral-popliteal bypass surgery during which the femoral nerve is exposed. An example of the setup for this intraoperative testing is shown in Fig. 6 . Any intraoperative testing requires an approved protocol by the institutional review board (IRB) and eligible patients must consent prior to testing. Potential patients are informed that the testing may add time to the clinical surgical procedure and alter the risks of complications. As an added precaution, pre-operative and post-operative assessments of motor and sensory function should be performed to ensure that acute intraoperative testing does not cause any adverse effects.
Acute intraoperative testing has been performed with all three types of the cuff electrodes described prior to chronic installation in human feasibility studies. The spiral cuff electrode was tested with upper extremity nerves (Polasek et al., 2007) and the femoral nerve (Polasek et al., 2009a, b) . The FINE was tested with the femoral nerve (Schiefer et al., 2010) and the tibial and common peroneal nerves (Schiefer et al., 2013) . Finally, the C-FINE was tested intraoperatively with the femoral nerve (Freeberg, 2018) . To our knowledge, intraoperative testing for somatosensory neuroprostheses or pain management devices has not been reported. There is a need for the development of easily accessible biomarkers or measurable outcomes, such as somatosensory evoked potentials (SSEPs) recorded with electroencephalography (EEG) electrodes, during surgery for applications other than motor neuroprostheses.
Performance indices such as charge threshold, the minimum amount of charge needed to evoke a motor or sensory response, can readily be obtained during intraoperative testing. This information is crucial for designing an IPG for chronic implantation. Prior work showed that charge thresholds for recruitment of same muscle groups were not significantly different between the spiral, FINE, and C-FINE Schiefer et al., 2010) ; during these intraoperative tests on the human femoral nerve, reported charge thresholds were 18 + 12 nC with the spiral (Polasek et al., 2009a, b) , 21 ± 18 nC with the FINE (Schiefer et al., 2010) , and 19.7 + 6.2 nC with the C-FINE (Freeberg, 2018) .
Intraoperative testing is also an important confirmatory step that can verify the design decisions made in earlier translational steps, prior to chronic implants. For example, the selectivity of a new neural interface can be explored intraoperatively and acutely in a living human subject. This can be done via documentation of the stimulated responses with needle, wire or surface electromyography (EMG) recordings from the muscles innervated by the target nerve during surgery (Fig. 6) . Various algorithms to quantify selectivity by positively weighting EMG activation of the target muscle and penalizing the activation of nontarget muscles have been applied for this purpose (Durfee and MACLean, 1989; Fisher et al., 2013) . Such algorithms can run in realtime and provide instantaneous results during intraoperative testing. Joint moments can be estimated from EMG recordings in conjugation with a biomechanical model (Delp et al., 1990; Friederich and Brand, 1990; Schiefer et al., 2010 Schiefer et al., , 2008 . As alternative to EMG, instruments such as dynamometers could be utilized to assess selectivity by measuring generated joint moments. However, considerations such as portability of a selected instrument or difficulty in sterilization for use in an operating room should be taken into account.
Calculating selectivity intraoperatively, even during deployment of a fully implanted system intended for chronic use, is crucial for determining the recruitment overlap and identifying redundant channels. Some of the individual contacts within high-density cuff electrodes can be redundant and recruit overlapping axonal populations (Charkhkar et al., 2018; Freeberg et al., 2017) . Most available IPGs have a fixed number of output channels available for delivering stimulation, reflecting the competing design criteria of maximal functionality with minimal size and power consumption. Therefore, a subgroup of contacts with the desired functional outcomes and least amount of redundancy can be identified intraoperatively and connected directly to the IPG, ultimately eliminating the need for a percutaneous trial (see below). Alternatively, intraoperative results can challenge the underlying assumptions of a new neural interface, as well as the requirements for an IPG, and trigger an iteration in the development and translational process.
Clinical demonstration
Prior to planning a chronic implantation of a new nerve interface technology in a human, short-term clinical studies are designed to assess its performance and verify its operation. In this phase, the implanted electrodes can be accessed through temporary indwelling percutaneous leads or an internal stimulator which has already obtained FDA approval for an investigational use. Although a percutaneous interface requires daily cleaning and proper maintenance of the skin exit sites to prevent topical infections or irritation, they are generally well tolerated by recipients and FDA may not deem implanted devices that utilize them to present significant risks to the user if they are removed within 30 days of installation. Thus, these devices may not require an IDE approval for initial demonstration of clinical feasibility. Temporary percutaneous interfaces are routinely utilized in clinical spinal cord stimulators for pain and other neuromodulatory applications. They also have a long history in developmental systems for motor and sensory neuroprostheses for standing, walking, and hand grasp after paralysis (Marsolais and Kobetic, 1988 , 1987 Memberg et al., 2014 Memberg et al., , 1993 , and for restoring somatosensation to upper and lower-limb amputees (Charkhkar et al., 2018; Graczyk et al., 2016; Tan et al., 2015 Tan et al., , 2014 . The ultimate goal is to utilize the knowledge gained from the percutaneous stage to deploy both the electrodes and IPG at the same time in other subjects, as well as to set the specifications for new IPGs with enhanced capabilities, thus eventually eliminating the phase altogether for a particular application. Percutaneous interfaces can be maintained for longer duration studies of chronic performance and safety, in which case the IDE regulations will apply (Johnson, 2012) . In this section, we review two recent examples of clinical demonstrations of C-FINE technology for motor and sensory applications.
The first clinical demonstration of C-FINEs was accomplished for a standing neuroprosthesis where 8-contact C-FINEs were implanted bilaterally on femoral nerves in a volunteer with paraplegia resulting from an incomplete low cervical spinal cord injury. The access to the contacts in C-FINEs was through percutaneous leads exiting the body on upper lateral thighs. The target implant location was near the inguinal ligament, an anatomically challenging area for a neural interface because of the nerve movement during hip flexion and rotation. As such, the performance of the C-FINEs as well as the nerve health was consistently monitored during a 6-month percutaneous phase. Stimulation through individual C-FINE contacts showed consistent isolation of 3 independent knee extensor muscles with minimal hip flexion during this time. These observations were in agreement with prior results obtained from computational modeling and intraoperative tests suggesting 8-contact cuff configuration was selective enough to activate independent knee extensors (Schiefer et al., 2010) . The knee extension moments generated by stimulation through individual contacts reached 4 times higher than the amount required for standing and twice of the moment necessary for sit-to-stand transition. Significantly higher moments were achieved when stimulation was delivered through multiple contacts instead of individual ones, indicating recruitment of independent motor units by each contact. After three months of lowerlimb muscle exercise using the implanted system, the subject was able to stand in excess of 30 min while more than 90% of his body weight was supported by his legs. These results achieved with C-FINE technology were considered a significant improvement over prior implanted neuroprostheses for which the standing times were on the order of 10 min after a year of training (Fisher et al., 2008; Triolo et al., 2018) . Measures of nerve health such as nerve conduction velocities showed no major sign of clinically relevant trauma to the nerve due to the C-FINE during the 6 months post implant. No changes in amplitude and latencies of compound muscle action potentials in response to stimulation were observed during hip flexion, suggesting that C-FINE was flexible enough to accommodate nerve bending in proximity to the inguinal ligament. At the end of the percutaneous phase, 3 contacts per C-FINE which produced the strongest and the most consistent knee extension moments were selected to be attached to a fully implantable IPG due to its limited number of output channels. By the end of the Fig. 6 . The schematic of the intraoperative experimental setup for testing a FINE implanted on the human femoral nerve. A custom-made stimulator controlled by an external computer delivered electrical pulses to the FINE contacts. Electromyography (EMG) signals were collected from muscles innervated by the femoral nerve (shown here: quadriceps and sartorius), amplified, and converted into digital signals before being read into the computer. EMG processing occurred in real-time to determine muscle recruitment selectivity in response to stimulation through each FINE contact. Reproduced with permission of IOP Publishing (Schiefer et al., 2010) . percutaneous phase, 14 out of 16 total C-FINE contacts recruited the same muscles as they did perioperatively. This observation indicates that perioperative measurements could provide accurate estimates of the long-term performance of the C-FINE, an important finding that could facilitate identifying most useful contacts for connection to the IPG at the time of implant.
Successful restoration of plantar sensation in individuals with lower-limb amputation is another example of deploying C-FINEs in new anatomical locations and different user population (Charkhkar et al., 2018) . With the goal of developing sensory neuroprosthesis for lowerlimb amputees, C-FINEs with 16-contacts have been implanted on prebranch sciatic and post-branch tibial or peroneal nerves in the residual limbs of 3 unilateral transtibial amputees (up to the time of this report). The access to the C-FINE contacts were made possible via tandemwound percutaneous leads exiting the body on the upper thigh above the area of the leg covered by prosthesis liner to avoid any discomfort (Fig. 7) . Recipients were able to wear their prostheses 2-3 weeks after surgery when the incisions healed sufficiently. Electrical activation of the nerves through the C-FINEs produced sensations of various modalities (e.g., touch, pressure, movement), at discrete locations projected to the missing limb of each volunteer with physiologically relevant percept areas. The locations of percepts generated with the proximally implanted C-FINES overlapped with those from the distal cuffs. For example, in the 1 st participant, reported locations from the C-FINE on sciatic nerve covered 69% and 75% of the reported locations from CFINEs on tibial and common peroneal nerves, respectively. This observation confirmed that a 16-contact C-FINE on the pre-branch sciatic nerve is suitable for selectively activating sensory fibers that used to innervate distinct locations of the foot and ankle via the post-branch tibial and peroneal nerves. The charge density thresholds to elicit sensation remained under 45 μC/ cm 2 with no significant variations over the 7 months post-implant that they were monitored. No painful or unusual sensation was developed as a result of stimulation or presence of the implanted C-FINEs on the nerves, suggesting no sign of pressure or impingement. Furthermore, strength-duration curves indicated healthy nerve function with no sign of pathology.
Chronic clinical deployment
At the time of this writing, spiral cuffs, FINEs, and C-FINEs have continued to function successfully in human recipients for up to 13 years, six years, and three years, respectively. The long-term functionality of an interface was defined as stable charge thresholds over time, consistent recruitment of muscle groups responsible for a desired function for motor neuroprostheses, and stability of percept locations as well as sensation quality for sensory neuroprostheses. Specifically, a long-term clinical and technical follow-up study demonstrated that spiral nerve cuff electrodes remained functional in 14 human recipients of motor or sensory neuroprostheses over time frames spanning 2-11 years post-implantation (Christie et al., 2017) . Of the 27 spiral cuff electrode contacts evaluated, only eight had a significant increase in charge threshold over time (linear regression, p < 0.05). Four individuals with spinal cord injury were implanted with monopolar spiral cuff electrodes on their bilateral femoral nerves. When tested more than Fig. 7 . 16-contact C-FINEs implanted on the pre-branch sciatic nerve and post-branch tibial and common peroneal nerves above the knee in the residual limb of a trans-tibial amputee (left and right bottom). The access to the C-FINE contacts was via temporary percutaneous leads exiting the body on the upper thigh (left and right top).
H. Charkhkar, et al. Journal of Neuroscience Methods 328 (2019) 108414 2-4 years after implantation, knee extension moments exceeded the 0.135 Nm/kg required to stand upright. Two of these individuals also had monopolar spiral nerve cuff electrodes on their bilateral common peroneal nerves, which exceeded the 0.01 Nm/kg required to prevent foot drop. Finally, in two individuals implanted with 4-contact spiral cuffs on their bilateral femoral nerves for several years, the electrode contacts were still selective for different motor populations. Similarly, longitudinal measurements in the first recipient of the C-FINE made more than three years after removal of the percutaneous leads and installation of the IPG revealed no significant change in the charge threshold required to elicit motor responses (Freeberg, 2018) . After 1 year of muscle-strengthening exercises using C-FINEs on the bilateral femoral nerves, visible improvements were noted in quadriceps muscle bulk and the generated isometric moments increased an average of 79%. The devices also continue to show consistent selectivity in muscle recruitment (Freeberg, 2018) .
Over six years after 8-contact FINEs were implanted on upper-extremity nerves for sensory neuroprostheses, two trans-radial amputees continue to describe discrete somatosensory percepts referred to their missing hands in response to electrical stimulation. (Graczyk et al., 2018; Tan et al., 2015) . These two subjects finished a short-term takehome trial during which quantitative and qualitative assessments were performed to examine the subjective user experience of the restored sensation's impact in their daily-life activities. These user experiences suggested improved embodiment of the prosthesis, positive effects on their interpersonal interactions, and increased confidence in performing motor tasks using their prosthetic limb (Graczyk et al., 2018) .
Conclusion
We presented a framework consisting of series of steps required for the successful translation of a neural interface from concept to chronic clinical deployment. The examples were drawn from various neural interfaces that had completed this process and had shown reliable clinical performance for motor and sensory neuroprostheses. The suggested framework demonstrates how knowledge gained from chronic performance in vivo, anatomy, realistic computational modeling, and acute clinical assessments can inform any design modifications and provide an estimate of the device's chronic function in human recipients. Although the presented framework identifies key considerations in transitioning from design concept to feasibility studies, additional steps should be taken to complete the translational process and bring a technology to market. These steps include early and active engagement with the FDA and payers such as insurance companies or Centers for Medicare and Medicaid Services to seek their input on the type of evidence, which would meet their criteria for evaluation of a new device. This article did not intend to provide any specifics regarding required evidence for an FDA submission. FDA guidelines should be consulted to acquire about any necessary tests or supporting data for a pre-market evaluation. Although provided examples were specific to cuff technology, the methodologies described in this article could be applicable to other neural targets or interface technologies, especially for new applications in the autonomic nervous system for which the neural maps are not well known.
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